Suppressive Effects of Vascular Endothelial Growth Factor-B on Tumor Growth in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis by Albrecht, Imke et al.
Suppressive Effects of Vascular Endothelial Growth
Factor-B on Tumor Growth in a Mouse Model of
Pancreatic Neuroendocrine Tumorigenesis
Imke Albrecht1, Lucie Kopfstein1, Karin Strittmatter2, Tibor Schomber1, Annelie Falkevall4,5, Carolina E.
Hagberg4,5, Pascal Lorentz1, Michael Jeltsch3, Kari Alitalo3, Ulf Eriksson4,5, Gerhard Christofori1, Kristian
Pietras4*
1Department of Biomedicine, Institute of Biochemistry and Genetics, University of Basel, Basel, Switzerland, 2German Cancer Research Center Heidelberg (DKFZ),
Heidelberg, Germany, 3Molecular and Cancer Biology Program, Biomedicum, University of Helsinki, Helsinki, Finland, 4Division of Vascular Biology, Department of
Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, 5 Ludwig Institute for Cancer Research Ltd, Stockholm Branch, Karolinska Institutet,
Stockholm, Sweden
Abstract
Background: The family of vascular endothelial growth factors (VEGF) contains key regulators of blood and lymph vessel
development, including VEGF-A, -B, -C, -D, and placental growth factor. The role of VEGF-B during physiological or
pathological angiogenesis has not yet been conclusively delineated. Herein, we investigate the function of VEGF-B by the
generation of mouse models of cancer with transgenic expression of VEGF-B or homozygous deletion of Vegfb.
Methodology/Principal Findings: Ectopic expression of VEGF-B in the insulin-producing b-cells of the pancreas did not alter
the abundance or architecture of the islets of Langerhans. The vasculature from transgenic mice exhibited a dilated
morphology, but was of similar density as that of wildtype mice. Unexpectedly, we found that transgenic expression of
VEGF-B in the RIP1-Tag2 mouse model of pancreatic neuroendocrine tumorigenesis retarded tumor growth. Conversely,
RIP1-Tag2 mice deficient for Vegfb presented with larger tumors. No differences in vascular density, perfusion or immune
cell infiltration upon altered Vegfb gene dosage were noted. However, VEGF-B acted to increase blood vessel diameter both
in normal pancreatic islets and in RIP1-Tag2 tumors.
Conclusions/Significance: Taken together, our results illustrate the differences in biological function between members of
the VEGF family, and highlight the necessity of in-depth functional studies of VEGF-B to fully understand the effects of
VEGFR-1 inhibitors currently used in the clinic.
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Introduction
The formation of new blood vessels, angiogenesis, is a complex
and tightly regulated process governed by the action of endo-
genous pro- and anti-angiogenic factors [1]. The members of the
vascular endothelial growth factor (VEGF) family represent
prototypical inducers of blood and lymph vessel formation.
However, despite our growing knowledge of the molecular cues
involved in shaping a new vasculature, the regulation of
physiological and pathological blood vessel formation by VEGFs
is still not completely understood. The VEGF family is comprised
of five members that bind and activate three receptor tyrosine
kinases (VEGFR-1, -2 and -3) with different specificity [2].
Haploinsufficiency of Vegfa in mice provides an illustrative example
of the importance of VEGF-A signaling through VEGFR-1 and -2
for proper endothelial cell function [3,4]. Placental growth factor
(PlGF) binds exclusively to VEGFR-1, and targeting of PlGF
inhibits angiogenesis in various pathological settings, including
tumor growth [5]. Furthermore, through binding to VEGFR-3 on
lymphatic endothelial cells, VEGF-C and -D predominantly
regulate lymphangiogenesis [6], even though VEGFR-3 expres-
sion by tumor blood vessels has also been reported [7]. VEGF-B
specifically binds and activates VEGFR-1, either alone or in
conjunction with the co-recpetor neuropilin-1. However, the
function of VEGF-B signaling in the context of pathological
angiogenesis remains elusive [8].
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VEGF-B was first identified as an endothelial cell mitogen
highly expressed in heart and skeletal muscle [9]. Consequently,
transgenic expression of VEGF-B through adenoviral delivery
readily induces angiogenesis in the myocardium [10]. However,
VEGF-B deficient mice do not display any overt vascular
abnormalities in the unchallenged heart vasculature, even though
an impaired recovery from cardiac ischemia is suggestive of an
underlying vascular dysfunction [11,12]. Moreover, ectopic
expression of VEGF-B in skeletal muscle does not induce
angiogenesis [10]. Most recently, a role for VEGF-B in the
trans-endothelial transport of lipids through regulation of fatty acid
transport proteins (FATPs) was described [13]. High expression of
VEGF-B is observed in a wide variety of tumors, including colon,
breast and kidney carcinoma [14,15,16,17]. Expression of VEGF-
B is predictive of lymph node metastasis in breast and colon
carcinoma, as well as a prognostic factor for shorter survival in
node positive breast cancer patients [14,17,18]. Intriguingly, the
intratumoral level of VEGF-B correlates with microvessel density
in oral squamous cell carcinomas, but is not indicative of
angiogenesis in breast carcinoma [14,19].
In order to shed light on the role of VEGF-B in tumor biology
in general, and angiogenesis in particular, we analyzed mice with
transgenic expression of VEGF-B, and mice deficient for Vegfb, in
the context of the multistep tumor progression pathway of
pancreatic islet carcinoma in RIP1-Tag2 mice [20]. Unexpectedly,
ectopic expression of VEGF-B under the insulin promoter reduced
the growth of tumors, whereas mice lacking VEGF-B presented
with larger tumors. No gross quantitative differences in the
vasculature were observed, neither in tumors nor in normal tissues
upon altered VEGF-B gene dosage. However, blood vessel
morphology was altered in the sense that transgenic expression
of VEGF-B yielded thicker vessels, whereas blood vessels in Vegfb-
deficient tumors appeared slimmer. Together, the data confirm
and extend the notion that the various VEGF family members
exert different functions in tissue homeostasis and carcinogenesis.
Further in-depth investigations are warranted to delineate the
detailed functional contribution of VEGF-B to tumor angiogenesis
and tumor progression in order to fully understand the complex
clinical effects of agents incorporating inhibitory action against
VEGFR-1.
Results
Transgenic expression of VEGF-B in pancreatic b-cells
alters microvessel morphology
To investigate the role of VEGF-B in normal and pathological
angiogenesis, we generated transgenic mice expressing the human
VEGF-B167 isoform under the control of the rat insulin promoter
(RIP1-VEGFB mice), thus directing expression of VEGF-B to the
b-cells of the pancreatic islets of Langerhans. Human VEGF-B167
activates VEGFR-1 downstream target genes FATP3 and FATP4
to the same extent as mouse VEGF-B167 and VEGF-B186 isoforms
in the mouse pancreatic islet endothelial cell line MS1, indicating
that human VEGF-B readily binds mouse VEGFR-1 (Figure S1).
Expression of the transgene in vivo was confirmed by immuno-
staining of tissue sections from the pancreas of RIP1-VEGFB mice
for human VEGF-B (Figure 1a). No changes were found in the
pancreatic islets of transgenic mice in terms of islet architecture,
number, or size (Figure S2a-c). Moreover, b-cell density and
functionality, as measured by glucose tolerance tests, were normal
in RIP1-VEGFB mice (Figure S2d-e). Next, we analyzed the
effects of the transgenic expression of VEGF-B on the vascular tree
by immunostaining for the endothelial cell marker CD31 and by
perfusion with fluorescein-labeled tomato lectin. Whereas there
was no difference in the number of islet blood vessels (vascular
density; Figure 1a-b), pancreatic islets of RIP1-VEGFB mice
exhibited a 20% increase in the fraction of the islet area covered
by vessels, as compared to wildtype mice (Figure 1a–b; 13.260.6%
vs 11.060.6%, p,0.05). The increase in vessel area was
consequent to an apparent increase in the diameter of pancreatic
islet microvessels from 8.060.25 mm in non-transgenic mice to
9.760.50 mm in RIP1-VEGFB mice (Table 1; p,0.01), while
vessel length was unchanged (Table 1). No overt differences in
perfusion of the islet capillaries were noted (Figure 1a). Finally, to
investigate whether islets of Langerhans from RIP1-VEGFB mice
exhibited an increased angiogenic potential, we made use of an ex
vivo collagen gel sprouting assay. Pancreatic islets were purified by
limited collagenase digestion of the pancreas, and subsequently
seeded into collagen gels together with human umbilical vein
endothelial cells (HUVEC). Factors produced by the islet will
diffuse into the gel and affect the phenotype of the co-cultured
endothelial cells. Islets from RIP1-VEGFA mice were used to
demonstrate migration and sprouting of HUVEC towards the islet
upon the release of an angiogenic factor (Figure 1c). Whereas 30%
of islets from RIP1-VEGFA mice exhibited angiogenic properties,
only 13.6% of islets from RIP1-VEGFB mice were able to attract
the co-cultured endothelial cells (Figure 1c). No islets from
wildtype mice were overtly angiogenic in this assay (Figure 1c).
Taken together, transgenic expression of VEGF-B167 in islets of
Langerhans increases microvessel diameter, but does not affect
islet functionality.
Transgenic expression of VEGF-B reduces tumor growth
in RIP1-Tag2 mice
The consequences of VEGF-B expression on tumor angiogen-
esis was assessed in the RIP1-Tag2 mouse model of islet cell
carcinoma; a model that has been widely used to study tumor
angiogenesis [21,22,23,24,25,26,27]. Quantitative reverse-tran-
scription polymerase chain reaction (qRT-PCR) revealed that
VEGF-B is readily detectable in normal b-islets of the mouse
pancreas, and maintained at similar levels during the progression
through hyperplastic islets and angiogenic islets into overt
carcinomas in RIP1-Tag2 mice (data not shown). A cell line
established from a RIP1-Tag2 tumor, b-TC3 [28], did not express
the bona fide receptor for VEGF-B, VEGFR-1, and was not
affected in its growth rate by VEGF-B (data not shown).
Moreover, tumorous b-cells isolated from RIP1-Tag2 tumors did
not express VEGFR-1 mRNA, in contrast to isolated blood
endothelial cells from the same tumors (Figure 2a), making it likely
that potential effects of transgenic expression of VEGF-B on tumor
progression in RIP1-Tag2 mice are caused by paracrine
stimulation. Double-transgenic RIP1-Tag2; RIP1-VEGFB mice
expressed VEGF-B protein in pancreatic islets at high levels
throughout the tumor progression pathway, as determined by
immunostaining for human VEGF-B (Figure 2b). Moreover,
tumors from RIP1-Tag2; RIP1-VEGFB mice contained abundant
levels of human VEGF-B mRNA, as assessed by qRT-PCR, and
protein, as assessed by ELISA (Figure S3a–b). No compensatory
change was noted in the expression of mouse VEGF-B upon
transgenic expression of human VEGF-B (Figure S3a).
While RIP1-Tag2; RIP1-VEGFB mice presented with a similar
number of tumors as RIP1-Tag2 mice (Figure 2c, left), expression
of the VEGF-B transgene unexpectedly resulted in a significant
reduction in total tumor burden by 39% (Figure 2c, right;
59.068.2 mm3 vs 35.764.2 mm3; p,0.05). No difference in local
tumor invasiveness was observed as a consequence of VEGF-B
expression (Figure S4a). Next, we analyzed the growth of b-cells in
tumor lesions. Neither the proliferative index, as assessed by BrdU
VEGF-B in Tumor Biology
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incorporation (Figure 2d, left) and phospho-Histone-3 staining
(Figure S4b), nor the apoptotic index, as assessed by TUNEL assay
(Figure 2d, right) and immunostaining for activated caspase-3
(Figure S4c), was significantly changed in double-transgenic RIP1-
Tag2; RIP1-VEGFB mice as compared to single-transgenic RIP1-
Tag2 mice. Also, no difference in terms of tumor cell density was
observed (Figure S4d). Possibly, transgenic expression of VEGF-B
produces subtle changes in the proportion of cells in different cell
cycle stages, including quiescent cells in G0, thus retarding overall
tumor growth. Recently, new roles for VEGF-B in the regulation
of pro-apoptotic members of the Bcl-2 family and in the regulation
of expression of FATPs in the endothelium were described
[10,29,30]. However, we found no VEGF-B-dependent changes in
the expression of BH3-only proteins, or of FATPs, in whole tumor
lysates, and there was no discernible difference in fatty acid
accumulation in RIP1-Tag2 lesions upon transgenic expression of
VEGF-B (Figure S5a–b).
Thus, expression of VEGF-B in the context of RIP1-Tag2
tumorigenesis significantly retarded tumor growth without affect-
ing the rates of proliferation or apoptosis of b-tumor cells.
Microvessels of RIP1-Tag2 tumors have a thicker
diameter upon transgenic expression of VEGF-B
To assess whether VEGF-B, by signaling through its receptor
VEGFR-1 on endothelial cells, affects the angiogenic phenotype of
RIP1-Tag2 tumors, we analyzed vascular parameters in RIP1-
Tag2; RIP1-VEGFB mice. Immunostaining for the endothelial
cell marker CD31 revealed no difference in the blood vessel
content of VEGF-B-expressing lesions, compared to control
lesions (Figure 3a–b). In keeping with the increase in vessel
diameter of pancreatic islets in RIP1-VEGFB mice, tumors from
RIP1-Tag2; RIP1-VEGFB mice exhibited a similar thickening of
microvessels compared to tumors from RIP1-Tag2 mice (Table 1;
11.060.64 mm vs 9.360.46 mm, p,0.05). Furthermore, the extent
of NG2+ pericyte coverage of tumor microvessels (RIP1-Tag2:
94.3% 6 0.87% vs RIP1-Tag2; RIP1-VEGFB: 94.3% 6 0.62%
of all vessels were covered with NG2), as well as the functionality
of the vasculature, as quantified by perfusion with fluorescein-
labeled tomato lectin (RIP1-Tag2: 93.1% 6 1.4% vs RIP1-Tag2;
RIP1-VEGFB: 93.5% 6 1.4% of all vessels were lectin perfused),
remained unaffected by the expression of VEGF-B (Figure 3c).
To assess whether the gross angiogenic profile was changed
upon transgenic expression of VEGF-B, we analyzed the
expression of VEGFRs and of prototypical angiogenic factors in
RIP1-Tag2 tumors by qRT-PCR. Neither the expression of other
VEGF family members, such as VEGF-A and PlGF, nor the
expression of PDGF-BB, FGF2 or Angiopoietin-2, was altered by
the presence of the VEGF-B transgene (Figure 3d). Moreover, the
protein levels of VEGFR-1 and VEGFR-2 remained unchang-
ed upon ectopic VEGF-B expression in RIP1-Tag2 tumors
(Figure 3e). Finally, islets from 12-weeks old RIP1-Tag2 mice
were embedded in collagen to ascertain whether they harbored
angiogenic properties ex vivo. Islets from single-transgenic RIP1-
Tag2 mice were deemed to be overtly angiogenic in 57% of the
cases (Figure 3f). Expression of VEGF-B in the purified islets
marginally increased the incidence of angiogenic islets to 72%
(Figure 3f).
In summary, while producing an increased thickness of tumor
microvessels, expression of VEGF-B neither affected vessel
abundance, architecture and function, nor angiogenic factor
profile in tumors of RIP1-Tag2 mice.
Immune cell infiltration is not altered by expression of
VEGF-B in RIP1-Tag2 lesions
Apart from its role in endothelial cell biology, VEGFR-1 is also
expressed by various cells of the immune system, including
macrophages [31] and hematopoietic progenitor cells [32]. Thus,
we appraised the effects of transgenic expression of VEGF-B on
the immune cell infiltration of RIP1-Tag2 lesions. As determined
by immunostaining for CD45, there was no gross difference in the
abundance of leukocytes in RIP1-Tag2; RIP1-VEGFB mice
compared to wildtype RIP1-Tag2 mice (Figure 4a-b). Specifically,
both macrophages and neutrophils have been implicated in the
growth and angiogenesis of RIP1-Tag2 tumors [33,34]. However,
Table 1. Vessel parameters for pancreatic islets or tumors from RIP1-VEGFB, RIP1-Tag2; RIP1-VEGFB, and RIP1-VEGFB2/2 mice.
Mouse line Tissue Mean vessel length (mm) Mean vessel diameter (mm)
C57Bl/6 Islets 40.262.0 8.060.25
RIP1-VEGFB Islets 43.763.8 9.760.50*
RIP1-Tag2 Tumors 48.862.06 9.360.46
RIP1-Tag2; RIP-VEGFB Tumors 48.960.25 11.060.64**
RIP1-Tag2; VEGFB+/2 Tumors 46.361.3 9.862.6
RIP1-Tag2; VEGFB2/2 Tumors 41.861.41 7.360.34***
*p,0.01 vs wt; ** p,0.05 vs RIP1-Tag2; *** p,0.0001 vs RIP1-Tag2; VEGFB+/2;
1p,0.05 vs RIP1-Tag2; VEGFB+/2.
doi:10.1371/journal.pone.0014109.t001
Figure 1. Characterization of angiogenesis in pancreatic islets from RIP1-VEGFB mice. A) Pancreatic sections of control C57BL/6 (left) and of RIP1-
VEGFB mice (right) were stained for human VEGF-B (red) to detect transgene expression (upper panel), for CD31 (red) to examine intra-insular blood
vessel distribution (middle panel) and were perfusion stained with FITC-coupled tomato lectin to evaluate intra-insular blood vessel functionality
(lower panel). To visualize islets of Langerhans, pancreatic sections were co-stained with insulin. Nuclei were visualized by DAPI stain. Scale bar:
100 mm. B) Quantification of islet microvessel area and density of C57BL/6 (N= 5, n = 37) and RIP1-VEGFB (N= 4, n = 36) mice. Analysis was
performed by determination of the CD31 stained area (left panel) or CD31 counts (right panel) in relation to the islet area using computer-assisted
image analysis. * P = 0.0112. N= number of analyzed mice, n = number of islets. C) Islets isolated from RIP1-VEGF-A (n = 23, N = 2), RIP1-VEGFB167
(n = 60, N = 10) and C57BL/6 (n = 38, N = 9), mice were co-cultured with HUVEC in a collagen gel matrix and their ability to induce an angiogenic
response was determined. The data points represent the average from two independent experiments using C57Bl/6 and RIP1-VEGFB167 mice, while
all islets from RIP1-VEGFA mice were analyzed in a single experiment. n = number of islets, N = number of mice.
doi:10.1371/journal.pone.0014109.g001
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the infiltration of macrophages and neutrophils, as evaluated by
immunostaining for F4/80 and Gr1, respectively, was not altered
by the expression of VEGF-B in RIP1-Tag2 double transgenic
mice (Figure 4a-b).
RIP1-Tag2 mice genetically deficient for VEGF-B present
with larger tumors
To validate the unexpected reduction in tumor burden observed
following transgenic expression of VEGF-B in pancreatic islets, we
generated RIP1-Tag2 mice deficient for VEGF-B expression
(RIP1-Tag2; Vegfb 2/2). Initial analyses of the phenotype of 12-
weeks old RIP1-Tag2; Vegfb 2/2 demonstrated that the loss of
VEGF-B affected neither the number of pre-malignant angiogenic
islets, nor the number of tumors (Figure S6a and Figure 5a, left).
However, in agreement with the reduced tumor burden of RIP1-
Tag2; RIP1-VEGFB mice, the average tumor volume of RIP1-
Tag2; Vegfb 2/2 mice was increased by 81% compared to RIP1-
Tag2; Vegfb +/2 (33.6629.9 mm3 vs 18.6621.3 mm3; Figure 5a,
right; p,0.05). Tumorous b-cells of the pancreas exhibited a
significantly lower degree of apoptosis, as assessed by the TUNEL
assay, in RIP1-Tag2; VEGFB2/2 mice compared to RIP1-Tag2;
Vegfb +/2 mice, consistent with the increased tumor size (Figure 5b;
p,0.05). There was no difference in the fraction of tumor cells
that expressed the proliferative marker Ki67 (Figure S6b). Next,
we analyzed the vascular tree of pancreatic lesions from RIP1-
Tag2; Vegfb 2/2 mice. The fraction of tumor area covered by
CD31+ endothelial cells was significantly lower in mice deficient
for Vegfb (Figure 5c; p,0.05). Nevertheless, the vessel density
(number of vessels per high power field) was similar, regardless of
Vegfb gene dosage (data not shown) and vessel length was only
marginally decreased (Table 1; p,0.05). Strikingly, microvessels of
RIP1-Tag2; Vegfb 2/2 lesions were thinner than in VEGF-B
proficient tumors (Figure 5d and Table 1; mean vessel diameter
7.360.34 mm vs 9.862.6 mm; p,0.0001), accounting for the
reduced total vessel surface area. However, no change in the
extent of pericyte coverage due to the absence of VEGF-B was
detected by immunostaining for the pericyte marker NG2 (RIP1-
Tag2; Vegfb +/2: 94% 6 2.1% vs RIP1-Tag2; Vegfb 2/2: 92.3% 6
3.1% of all vessels were covered with NG2) (Figure 5e). Finally,
neither immune cell infiltration, as assessed by quantification of
CD45+ cells within RIP1-Tag2 tumors, nor lipid accumulation
was different in RIP1-Tag2; Vegfb 2/2 mice compared to RIP1-
Tag2; Vegfb +/2 mice (Figure S6c and data not shown).
Thus, in agreement with the reduced tumor size upon
transgenic expression of VEGF-B in tumorous pancreatic b-cells,
Vegfb-deficient RIP1-Tag2 mice present with larger tumors that
harbor morphological changes in the vascular bed.
Discussion
A definitive role for VEGF-B in tumor biology has thus far not
been defined, and there is an apparent paucity of pre-clinical
studies investigating the function of tumor-derived VEGF-B. Our
finding that VEGF-B gene dosage correlates inversely with tumor
growth was unexpected in the light of the prominent and well-
documented role of other members of the VEGF family in tumor
angiogenesis. Specifically in RIP1-Tag2 mice, overexpression of
VEGF-A accelerates tumor progression and growth by facilitating
activation of the angiogenic switch [35]. On the other hand,
depletion of VEGF-A in the pancreatic b-cells by genetic means
essentially eliminates tumor progression beyond the angiogenic
stage [21]. The diversity of outcomes in functional studies of
VEGF family members is further highlighted by the fact that
neutralization of PlGF or blockade of VEGFR-1 in RIP1-Tag2
mice does not affect tumor angiogenesis or growth [26,36]. To
understand the mechanism behind the observed outcomes, the
VEGFR-1 and VEGFR-2 occupancy by all different VEGF
ligands in the context of ligand over-expression or deficiency have
to be considered. In the present study, the transgenically expressed
VEGF-B in RIP1-Tag2 islets possibly displaced VEGF-A and
PlGF from VEGFR-1, thus diminishing signaling by overtly pro-
angiogenic factors. Conversely, the absence of VEGF-B in RIP1-
Tag2; Vegfb2/2 mice may enhance the specific signaling by
VEGF-A and PlGF through VEGFR-1 in endothelial cells.
Moreover, members of the VEGF family have been reported to
form heterodimers, the abundance and activity of which is
presently still unknown [37,38,39]. Additional complexity comes
from possible effects on the competitive binding equilibrium of the
VEGF family co-receptors neuropilin-1 and -2 [40], which also act
as an integral part of the semaphorin and plexin family of
angiogenesis regulators [41]. Clearly, more in-depth studies of
VEGFR ligand and receptor/co-receptor occupancy following
various pharmacological and/or genetic perturbations of the
VEGF system are warranted together with functional studies
aimed at revealing ligand-specific signaling effectors downstream
of VEGFR-1.
A number of possible explanations for the observed effects of
VEGF-B on tumor growth relating to cell metabolism or energy
usage are discussed below. Firstly, VEGF-B was recently attributed
a role in metabolism by controlling the trans-capillary transport of
long-chain fatty acids through transcriptional regulation of FATPs
in the endothelium [10,30]. Thus, the release of VEGF-B would
allow tissues with a high metabolic turnover, including tumors, to
meet their demand for fuel. In the context of pancreatic b-cell
biology, excess lipid exposure is known to be detrimental for both
b-cell function and survival [42]. Moreover, free fatty acids induce
the production of the vasodilator nitric oxide in pancreatic islets
[43]. Interestingly, indications of diminished lipotoxicity in tumors
from RIP1-Tag2; Vegfb2/2 mice come from the observations of a
decreased rate of b-cell apoptosis and a constricted vasculature.
However, we did not observe increased b-cell apoptosis or tumoral
lipid accumulation and fatty acid transporter protein expression in
RIP1-Tag2; RIP1-VEGFB tumors. Thus, it is unlikely that the
observed changes in tumor growth rate result solely from changes
in lipid accumulation and toxicity. Secondly, tumors preferentially
meet their energy demand through glycolysis [44]. Studies of
patients with colorectal carcinoma using positron emission
tomography (PET) demonstrate an inverse correlation between
the expression of VEGF-B and k3, the most important kinetic
parameter for determining uptake of the glucose analog 18F-FDG
[45]. Whether the observed VEGFB-dependent changes in tumor
growth rate in the RIP1-Tag2 model are due to an altered supply
Figure 2. Characterization of the phenotype of tumors from RIP1-Tag2; RIP1-VEGFB mice. A) RT-PCR analysis of VEGF-R1 expression in GLP1R+ b-
tumor-cells and CD31+ tumor-derived blood-endothelial cells (BEC) isolated from 12 weeks old RIP1-Tag2 mice. B) Pancreatic tumor sections of control
RIP1-Tag2 (left) and RIP1-Tag2; RIP1-VEGFB (right) mice were stained for human VEGF-B (red) to detect transgene expression. Nuclei were counterstained
with DAPI. T = Tumor, E = Exocrine pancreas. Scale bar: 100 mm. C) Tumor incidence (left) and volumes (right) of RIP1-Tag2 (N= 36) and RIP1-Tag2; RIP1-
VEGFB (N= 38) mice were determined at the age of 12 weeks. Single points represent the total tumor volume (or tumor number) per mouse as
indicated. * P = 0.0149 (Student’s t-test). D) Tumor cell proliferation (left) and apoptosis (right) in RIP1-Tag2 and RIP1-Tag2; RIP1-VEGFB mice was
determined by counting the number of BrdU and TUNEL positive tumor cells in a total of 7 to 10 microscopic fields (magnification 4006) per mouse.
doi:10.1371/journal.pone.0014109.g002
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Figure 3. Characterization of the vascular and angiogenic profile of tumors derived from RIP1-Tag2; RIP1-VEGFB mice. A) Representative
immunofluorescence microphotographs of pancreatic tumor sections of RIP1-Tag2 (left) and RIP1-Tag2; RIP1-VEGFB (right) mice stained for CD31.
Scale bar: 100 mm. B) Quantification of intratumoral vessel density in RIP1-Tag2 (N= 5, n = 20) and RIP1-Tag2; RIP1-VEGFB (N= 5, n = 20) was
performed using computer-assisted image analysis. Results are displayed as relation of CD31 stained area or CD31 positive cell counts to tumor area.
VEGF-B in Tumor Biology
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or utilization of glucose warrants further analysis by a PET-based
approach.
Pharmacological inhibitors of VEGF-signaling have now made
their way into the clinic following successful pre-clinical studies.
However, the patient benefit is comparatively modest and is
typically measured in months [46,47,48]. The mechanism of
action of VEGF inhibitors is still debated and has been suggested
to include overt anti-angiogenic actions, vessel ‘‘normalization’’,
inhibition of mobilization of endothelial precursor cells, suppres-
sion of intra-tumoral regulatory T-cells, as well as direct effects on
N= number of analyzed mice, n = number of islets. C) Representative immunofluorescence microphotographs of pancreatic tumor sections of RIP1-
Tag2 (left) and of RIP1-Tag2; RIP1-VEGFB (right) mice double-stained with CD31 and the pericyte marker NG2 (upper panel) or with FITC-coupled
tomato lectin (lower panel). Scale bar: 100 mm. D) Evaluation of mVEGFR-1, mVEGFR-2, mVEGF-A, mPlGF, mPDGF-BB, mFGF2 and mAng2 mRNA
expression by quantitative RT-PCR in total tumors of RIP1-Tag2 (n = 5) and RIP1-Tag2; RIP1-VEGFB (n = 5) mice. The mRNA expression profiles of the
indicated genes are normalized to the expression of the internal control gene ribosomal protein 19 (mRPL19). E) Upper panel: Immunoblot for
mVEGFR-1, mVEGFR-2 and vinculin (loading control) of total tumor lysate prepared from pancreatic tumors of a 12 weeks-old RIP1-Tag2 and RIP1-
Tag2; RIP1-VEGFB. Lower panel: Quantitation. F) Determination of the percentage of dysplastic islets isolated from RIP1-Tag2 (white bar, n = 24) and
RIP1-Tag2; RIP1-VEGFB mice (grey bar, n = 25) which are able to induce an angiogenic response when they were co-cultured with HUVECs in a
collagen gel matrix.
doi:10.1371/journal.pone.0014109.g003
Figure 4. Analysis of inflammatory cell infiltration in tumors derived from RIP1-Tag2; RIP1-VEGFB mice. A) Representative immunofluorescence
microphotographs of pancreatic tumor sections of RIP1-Tag2 (left) and RIP1-Tag2; RIP1-VEGFB (right) mice stained for CD45. Scale bar: 100 mm.
B) Quantification of tumor-infiltrating immune cells in RIP1-Tag2 (white bar, N = 5, n = 26-46) and RIP1-Tag2; RIP1-VEGFB (grey bar, N = 5, n = 27–45).
The number of tumor-infiltrating CD45+ and F4/80+ cells as well as 7/4+ neutrophils was determined by quantification of the area stained for the
selected marker in relation to the total tumor area using computer-assisted image analysis. N = number of analyzed mice, n = number of tumors.
doi:10.1371/journal.pone.0014109.g004
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tumor cells [49]. Given the diversity and complexity of signaling
derived from the VEGF ligand/receptor system revealed by this
and other studies, it is important to fully understand the
contributions of each component. Despite the observed inhibition
of tumor growth in the present study, human tumors, as well as
wildtype RIP1-Tag2 tumors, readily express VEGF-B, indicative
of functional significance. Again, it may be that a balance between
the three different VEGFR-1 ligands must be maintained to
achieve optimal conditions for endothelial cell function and
growth. Our results raise the possibility that indiscriminate
blocking of VEGF signaling may lead to a mix of favorable and
detrimental effects in terms of net tumor growth. Thus, further
pre-clinical as well as clinical studies on the role of VEGF-B in
tumor biology in the context of pharmacological inhibition of
VEGF family signaling are justified in order to maximize patient
benefit.
Materials and Methods
Mice
All experimental procedures involving mice were approved by
and performed according to the guidelines and regulations of the
local committees for animal care (the Swiss Federal Veterinary
Office (SFVO) - the Cantonal Veterinary Office of Basel Stadt,
permit numbers 1878, 1907, 1908, and Stockholm North
committee for animal experimentation, permit number N146/
08) and all efforts were made to minimize suffering.
The RIP1-VEGFB vector encodes full length human VEGF-
B167 (accession number EMBL: U43369) under the control of the
rat insulin gene II promoter (RIP1; [20]. For generation of
transgenic RIP1-VEGFB mice, a RIP1-VEGFB fragment, ob-
tained by BamH1 digestions of the RIP1-VEGFB vector was
injected into the pronucleus of fertilized C57BL/6 oocytes
according to standard protocol [50]. The genotypes of founder
animals were confirmed by PCR analysis of genomic DNA using
the primer pair 59-TAA TGG GAC AAA CAG CAA AG-39 and
59-CGC GAG TAT ACA CAT CTA TCC-39.
Double-transgenic RIP1-Tag2; RIP1-VEGFB mice were ob-
tained by crossing the single-transgenic RIP1-VEGFB mice with
RIP1-Tag2 mice. All mice were kept on C57BL/6 background.
RIP1-Tag2 mice deficient mice were obtained by crossing RIP1-
Tag2 mice with homozygous null mice for Vegfb, after which the
heterozygote offspring was again backcrossed to homozygous null
mice [11,12].
Phenotypical analysis of all mice and their littermates were
performed between the age of 10 and 12 weeks. Tumor incidence
per mouse was determined by counting the numbers of
macroscopically visible pancreatic tumors with a diameter above
1 mm. Tumor volume was calculated from the measured tumor
diameter assuming a spherical tumor shape. To measure tumor
cell proliferation using bromodeoxyuridine, mice were injected
intraperitoneally with 100 mg bromodeoxyuridine (Sigma) 90 min
prior to sacrificing of the animals.
To evaluate vessel functionality, anesthetized mice were tail
vein-injected with 100 ml of 1 mg/ml fluorescein-labeled Lycopersi-
con esculentum lectin (Vector Laboratories). After 5 min, mice were
heart-perfused consecutively with 10 ml 4% paraformaldehyde
and 10 ml PBS, and subsequently the pancreata were isolated.
Histopathological analysis
The isolated mice pancreata were either directly embedded in
OCT compound (Tissue Tek, Redding, CA) and snap frozen in
liquid nitrogen or fixed (2 hours in 4% paraformaldehyde followed
by incubation in 12%, 15%, 18% sucrose for 1 h each and 30%
sucrose O/N) before OCT embedding. For paraffin embedding,
the pancreata were fixed overnight in 4% paraformaldehyde and
dehydrated prior embedding. Immunostaining was performed on
paraffin sections (5 mm) or on cryosections (7 mm) as previously
described [25,35].
The following antibodies were used: rat anti-mouse CD31 and
rat anti-mouse CD45 (BD Pharmingen, Franklin Lakes, NJ), goat
anti-human VEGF-B167/186 (R&D Systems), rabbit anti-mouse
NG-2 (Chemicon, Hampshire, UK), rat anti-mouse neutrophils
(clone7/4), rat anti-mouse F4/80 (AbD Serotech), rabbit anti-
Ki67 (Novocastra laboratories, Newcastle, United Kingdom) the
in Situ Cell Death Detection Kit, POD (terminal deoxynucleotidyl
transferase-mediated nick end labeling (TUNEL); Roche) and
biotinylated mouse anti-BrdU (Zymed). Secondary antibodies for
immunofluorescence were conjugated either with AlexaFluor 488
or 568 (Molecular Probes). Nuclei were counterstained with 6-
diamidino-2-phenylindole (DAPI). Stained pancreata sections
were viewed on a Nikon Diaphot 300 immunofluorescence
microscope (Nikon, Egg, Switzerland) using Openlab 3.1.7.
Software (Improvision, Coventry, England) or on a Nikon Eclipse
E800 microscope equipped with Nikon Plan Fluor objectives.
Tumor microvessel density as well as the amount of tumor-
infiltrating immune cells was quantified using Image J software
(Rasband, W.S., ImageJ, U. S. National Institutes of Health,
Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997–
2007) and is displayed as % of stained intratumoral area to tumor
area or counts per tumor area. Lectin perfused and pericytes
covered tumor blood vessels are shown as % of the total
intratumoral vessels. To determine tumor cell proliferation and
apoptosis, BrdU/TUNEL/or Ki67 positive nuclei were counted in
randomly chosen 406 magnification fields of tumor tissue. Per
mouse approximately 10 fields were examined.
Microvessel diameter and length were quantified in C57Bl/6
(n= 233 vessel structures), RIP1-VEGFB (n= 254 vessel struc-
tures), RIP1-Tag2 (n= 2034 vessel structures), RIP1-Tag2; RIP1-
VEGFB (n = 1811 vessel structures), RIP1-Tag2; Vegfb+/2
(n = 2806 vessel structures), and RIP1-Tag2; Vegfb2/2 (n = 1775
vessel structures) using the Volocity Quantitation software package
Perkin-Elmer, Waltham, MA). Vessel diameter was taken as object
area divided by skeletal length.
RT-PCR
A single cell suspension of pancreatic tumors of 12 -week -old
RIP1-Tag2 mice was prepared by Dispase digestion. For
subsequent isolation of GLP-1R+ b-tumor cells and tumor-derived
CD31+ blood endothelial cells (BEC) by fluorescence-activated
cell sorting (FACS), cells were stained with FITC labeled
glucagon-like peptide 1 receptor (GLP-1R) peptide ligand
Figure 5. Characterization of the tumor and angiogenic phenotype of tumors derived from Vegfb-deficient RIP1-Tag2 mice. A) Quantification of
tumor number (left) and total tumor burden (right) of 12 weeks-old RIP1-Tag2; Vegfb +/2 (n = 30) and RIP1-Tag2; Vegfb 2/2 (n = 18) mice. B)
Quantification of tumor cell apoptosis in lesions (n = 40 for each genotype) from RIP1-Tag2; Vegfb +/2 and RIP1-Tag2; Vegfb 2/2 mice, as assessed by
TUNEL assay. C,D) Vascular density (C) and morphology (D) in lesions from RIP1-Tag2; Vegfb +/2 (n = 27) and RIP1-Tag2; Vegfb 2/2 (n = 23) mice. Scale
bar, 50 mm. E) Pericyte coverage (n = 24 for each genotype), as visualized by immunostaining for the pericyte marker NG2 (green) in relation to the
endothelial cell marker CD31 (red). Cell nuclei were visualized using DAPI (blue).
doi:10.1371/journal.pone.0014109.g005
VEGF-B in Tumor Biology
PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e14109
exendin-4 (Phoenix Pharmaceuticals, Inc.) and with APC-CD31
(Biolegend). Total RNA was extracted from isolated cells, cDNA
prepared and the expression of VEGF-R1 was evaluated by PCR.
The following primers were used:
mActin: ACACTGTGCCCATCTACGAGG and CATGCA-
TGCCACAGGATTCC
mCD31: GGAGTCAGAACCCATCAGGA and TACTGG-
GCTTCGAGAGCATT
mGLP-1R: TCAGAGACGGTGCAGAAATG and CAAGG-
CGGAGAAAGAAAGTG
mVEGF-R1: CGGCAGACCAATACAATCCT and CCGCT-
GCCTTATAGATGCTC.
Quantitative RT-PCR
Total RNA was extracted from isolated pancreatic tumors of
RIP1-Tag2 and RIP1-Tag2; RIP1-VEGFB mice using TRIzol
reagent. After DNase treatment of the RNA, first-strand cDNA
was synthesized with M-MLV reverse transcriptase RNAse-H
(Promega). Quantitative PCR for mouse Fatp1, 3, 4, Bik, Bmf,
VEGF-A, PlGF, PDGF-BB, FGF2 and Ang2 transcripts was done
on ABI Prism 7000 (Applied Biosystems) using the SYBR-green
PCR MasterMix (Applied Biosystems) and normalized versus the
mouse ribosomal protein 19 (mRPL19) transcript. The following
primers were used:
mRPL19: ATCCGCAAGCCTGTGACTGT and TCGGGC-
CAGGGTGTTTTT
mVEGF-A: ACTGGACCCTGGCTTTACTG and TCTGC-
TCTCCTTCTGTCGTG
mPlGF: CTGGGTTGGCTGTGCATT and GGCACCAC-
TTCCACTTCTGT
mPDGF-BB: CGAGGGAGGAGGAGCCTA and GTCTTG-
CACTCGGCGATTA
mFGF2: CGGCTCTACTGCAAGAACG and TGCTTGG-
AGTTGTAGTTTGACG
mAng2: CACACTGACCTTCCCCAACT and CCCACGTC-
CATGTCACAGTA
mVEGFR1: ACCTCCGTGCATGTGTATGA and ATGGA-
CAGCCGATAGGAC
mVEGFR2: AAAGCGGGACGAGGAGAG and CAGGTT-
GCACAGTAATTTCAG.
Collagen Gel Assay
Islets from C57BL/6, RIP1-VEGFA and RIP1-VEGFB mice or
dysplastic islets from RIP1-Tag2 and RIP1-Tag2; RIP1-VEGFB
mice were isolated at the age of 6 and 9 weeks respectively as
previously described [51]. The isolated islets were cultured
together with human umbilical vein endothelial cells (HUVEC)
in a three-dimensional collagen matrix for 2-3 days prior the
angiogenic response was analyzed. Approximately 30 islets were
scored per genotype.
Protein Analysis
Tumor lysate from pancreatic tumors of 12 week-old RIP1-
Tag2 and RIP1-Tag2; RIP1-VEGFB mice were prepared by
mechanical disruption of the tissue in JS lysis buffer (50 mM
HEPES pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 5 mM EGTA,
1% TritonX-100, 1% glycerol) containing proteinase inhibitor.
Lysates were cleared by centrifugation (12000 xg, 20 min).
Subsequently, equal protein amounts of the samples were
separated on a SDS-Page, transferred to PVDF membrane and
stained for mVEGFR-1 (Epitomics), mVEGFR-2 (Cell Signaling)
and vinculin (Santa Cruz). For quantitation fluorescent dye labeled
secondary antibodies (Li-Cor) were used. The fluorescent signals
was measured with the infrared imager odyssey (Li-Cor) and
analyzed by ImageJ software Rasband, W.S., ImageJ, U. S.
National Institutes of Health, Bethesda, Maryland, USA, http://
rsb.info.nih.gov/ij/, 1997–2007). Protein expression is displayed
as the ratio between fluorescent signal intensity of the protein of
interest and of the loading control vinculin.
Statistical analysis
All statistical analyses were performed using a Student’s un-
paired, two-sided t-test with p,0.05 considered significant.
Supporting Information
Figure S1 Comparison of the ability of mouse and human
VEGF-B to activate VEGFR-1 downstream target gene transcrip-
tion. Quantitative RT-PCR determination of the induction of
FATP3 and FATP4 mRNA by mouse pancreatic islet endothelial
cells (MS1) following 24h of stimulation by control, human VEGF-
B167, or mouse VEGF-B167 and VEGF-B186.
Found at: doi:10.1371/journal.pone.0014109.s001 (0.13 MB TIF)
Figure S2 Characterization of the pancreatic islet architecture in
RIP1-VEGFB mice. A) Pancreatic sections of control C57BL/6
(left) and of RIP1-VEGFB mice (right) stained for glucagon and
insulin to examine islet architecture. Nuclei were counterstained
with DAPI. Scale bar: 100 mm. B, C) Quantification of islet
number (B, left), area (B, right) and Beta-cell density (C) was
performed on H&E stained paraffin sections of C57BL/6 (N= 8)
and RIP1-VEGFB (N=6) mice. Determination of islet area and of
Beta-cell number per islet area was done using computer-assisted
image analysis. Beta-cell density is shown as nuclei per islet area in
mm2. *, p = 0.0108 (Student’s t-test). D) Intra-peritoneal glucose
tolerance test: After 16 hours of starvation C57BL/6 (N= 6) and
RIP1-VEGFB (N=6) mice were i.p. injected with 1g glucose/kg
body weight, and subsequently blood glucose levels were
determined at the indicated time points.
Found at: doi:10.1371/journal.pone.0014109.s002 (3.68 MB TIF)
Figure S3 Analysis of the expression of VEGFB in RIP1-
VEGFB mice. A) Quantitative RT-PCR determination of
expression of mouse and human VEGF-B in tumors from RIP1-
Tag2 and Rip1-Tag2; RIP1-VEGFB mice. B) Analysis of the
abundance of human VEGF-B protein in serum and tumor tissue
from RIP1-Tag2; RIP1-VEGFB mice using ELISA.
Found at: doi:10.1371/journal.pone.0014109.s003 (0.23 MB TIF)
Figure S4 Characterization of the phenotype of tumors derived
from RIP1-Tag2; RIP1-VEGFB mice. A) Staging of tumors into
normal/hyperplastic islets, adenoma or carcinoma in RIP1-Tag2
(N= 6) and RIP1-Tag2; RIP1-VEGFB (N= 6) mice. B, C, D)
Quantification of tumor cell proliferation in RIP1-Tag2 (N= 5,
n = 28) and RIP1-Tag2; RIP1-VEGFB (N= 5, n= 38) (B) mice,
of tumor cell apoptosis in RIP1-Tag2 (N= 4, n= 23) and RIP1-
Tag2; RIP1-VEGFB (N= 5, n= 29) mice (C) and of tumor cell
density in RIP1-Tag2 (N= 8, n = 32) and RIP1-Tag2; RIP1-
VEGFB (N=6, n= 32) (D) mice. Results are displayed as % of
phospho-Histone-3 (A), cleaved caspase-3 (B) or DAPI (D) stained
area in relation to the tumor area. N= number of analyzed mice,
n = number of tumors
Found at: doi:10.1371/journal.pone.0014109.s004 (0.68 MB TIF)
Figure S5 Analysis of the phenotypic consequence of VEGF-B
expression in RIP1-Tag2 tumors. A) Evaluation of mFatp1-3,
mBik and mBmf mRNA expression by quantitative PCR in total
tumors of RIP1-Tag2 (n= 5) and RIP1-Tag2; RIP1-VEGFB
(n= 5) mice. The mRNA expression profiles of the indicated genes
are normalized to the expression of the internal control gene
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ribosomal protein 19 (mRPL19). B) Oil red lipid stain of frozen
pancreatic tumor sections of RIP1-Tag2 (left) and RIP1-Tag2;
RIP1-VEGFB (right). The inset shows oil red stain of a liver
section. Scale bar: 100 mm.
Found at: doi:10.1371/journal.pone.0014109.s005 (4.07 MB TIF)
Figure S6 Characterization of the phenotype of tumors derived
from Vegfb-deficient RIP1-Tag2 tumors. A) Quantification of the
number of angiogenic islets in 12-weeks old RIP1-Tag2; Vegfb+/-
(n = 14) and RIP1-Tag2; Vegfb-/- (n = 8) mice. B) Quantification
of tumor cell proliferation in lesions from RIP1-Tag2; Vegfb+/-
(n = 27) and RIP1-Tag2; Vegfb-/- (n = 26) mice. C) Quantification
of the number of infiltrating immune cells in lesions (n = 24 for
each genotype) from RIP1-Tag2; Vegfb+/- and RIP1-Tag2;
Vegfb-/- mice depicted as average +/- standard deviation. Results
are displayed as % of stained area to tumor area.
Found at: doi:10.1371/journal.pone.0014109.s006 (0.33 MB TIF)
Materials and Methods S1
Found at: doi:10.1371/journal.pone.0014109.s007 (0.03 MB
DOC)
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